AstraZeneca’s first Breakthrough Therapy Designation for a respiratory medicine Designation based on Phase IIb PATHWAY data that demonstrated tezepelumab significantly…
Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence…
Imfinzi improves progression-free survival (PFS) by more than 11 months compared to standard of care and is the first medicine…
Phase III FLAURA trial results show Tagrisso reduced the risk of progression or death by more than half, with consistent…
CAMBRIDGE, 07-Aug-2017 — /EuropaWire/ — AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the…